Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $40.4 million.

  • Gyre Therapeutics' Cash & Equivalents rose 15410.06% to $40.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.4 million, marking a year-over-year increase of 15410.06%. This contributed to the annual value of $11.8 million for FY2024, which is 6474.68% down from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Cash & Equivalents is $40.4 million, which was up 15410.06% from $36.5 million recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Cash & Equivalents high stood at $107.0 million for Q1 2021, and its period low was $6.9 million during Q3 2023.
  • Over the past 5 years, Gyre Therapeutics' median Cash & Equivalents value was $29.8 million (recorded in 2024), while the average stood at $36.5 million.
  • As far as peak fluctuations go, Gyre Therapeutics' Cash & Equivalents tumbled by 8470.95% in 2023, and later surged by 15410.06% in 2025.
  • Over the past 5 years, Gyre Therapeutics' Cash & Equivalents (Quarter) stood at $46.9 million in 2021, then plummeted by 46.27% to $25.2 million in 2022, then soared by 33.1% to $33.5 million in 2023, then plummeted by 64.75% to $11.8 million in 2024, then skyrocketed by 242.01% to $40.4 million in 2025.
  • Its Cash & Equivalents stands at $40.4 million for Q3 2025, versus $36.5 million for Q2 2025 and $15.0 million for Q1 2025.